2348 Stock Overview
An investment holding company, develops, manufactures, and sells non-patented pharmaceutical medicines in Mainland China and internationally.
Snowflake Score | |
---|---|
Valuation | 2/6 |
Future Growth | 0/6 |
Past Performance | 3/6 |
Financial Health | 5/6 |
Dividends | 4/6 |
Dawnrays Pharmaceutical (Holdings) Limited Competitors
Price History & Performance
Historical stock prices | |
---|---|
Current Share Price | HK$1.13 |
52 Week High | HK$1.35 |
52 Week Low | HK$0.98 |
Beta | 0.72 |
11 Month Change | -5.83% |
3 Month Change | -5.04% |
1 Year Change | -7.38% |
33 Year Change | -35.06% |
5 Year Change | -13.74% |
Change since IPO | 172.29% |
Recent News & Updates
Dawnrays Pharmaceutical (Holdings)'s (HKG:2348) Dividend Will Be CN¥0.065
May 25Dawnrays Pharmaceutical (Holdings) (HKG:2348) Will Pay A Dividend Of CN¥0.065
Apr 22Recent updates
Dawnrays Pharmaceutical (Holdings)'s (HKG:2348) Dividend Will Be CN¥0.065
May 25Dawnrays Pharmaceutical (Holdings) (HKG:2348) Will Pay A Dividend Of CN¥0.065
Apr 22Dawnrays Pharmaceutical (Holdings) (HKG:2348) Has Announced A Dividend Of CN¥0.065
Apr 08Dawnrays Pharmaceutical (Holdings) (HKG:2348) Is Due To Pay A Dividend Of CN¥0.065
Mar 25Dawnrays Pharmaceutical (Holdings) (HKG:2348) Has Announced A Dividend Of CN¥0.015
Aug 30Dawnrays Pharmaceutical (Holdings)'s (HKG:2348) Shareholders Will Receive A Bigger Dividend Than Last Year
May 26Dawnrays Pharmaceutical (Holdings) (HKG:2348) Will Pay A Dividend Of CN¥0.073
Apr 04Dawnrays Pharmaceutical (Holdings)'s (HKG:2348) Dividend Will Be CN¥0.015
Sep 19Dawnrays Pharmaceutical (Holdings)'s (HKG:2348) Solid Profits Have Weak Fundamentals
Sep 22Dawnrays Pharmaceutical (Holdings) (HKG:2348) Will Pay A Dividend Of HK$0.015
Sep 12Dawnrays Pharmaceutical (Holdings)'s (HKG:2348) Dividend Will Be HK$0.015
Aug 29Here's How We Evaluate Dawnrays Pharmaceutical (Holdings) Limited's (HKG:2348) Dividend
Feb 28Would Shareholders Who Purchased Dawnrays Pharmaceutical (Holdings)'s (HKG:2348) Stock Five Years Be Happy With The Share price Today?
Feb 07Yung Lai Hung Is The Co-Founder & Executive Director of Dawnrays Pharmaceutical (Holdings) Limited (HKG:2348) And They Just Picked Up 34% More Shares
Jan 14Dawnrays Pharmaceutical (Holdings) Limited's (HKG:2348) Stock On An Uptrend: Could Fundamentals Be Driving The Momentum?
Dec 22What Kind Of Investors Own Most Of Dawnrays Pharmaceutical (Holdings) Limited (HKG:2348)?
Dec 09Three Things You Should Check Before Buying Dawnrays Pharmaceutical (Holdings) Limited (HKG:2348) For Its Dividend
Nov 23Shareholder Returns
2348 | HK Pharmaceuticals | HK Market | |
---|---|---|---|
7D | -0.9% | 5.4% | -1.7% |
1Y | -7.4% | 4.2% | -5.9% |
Return vs Industry: 2348 underperformed the Hong Kong Pharmaceuticals industry which returned 4.2% over the past year.
Return vs Market: 2348 underperformed the Hong Kong Market which returned -5.9% over the past year.
Price Volatility
2348 volatility | |
---|---|
2348 Average Weekly Movement | 2.6% |
Pharmaceuticals Industry Average Movement | 5.0% |
Market Average Movement | 6.5% |
10% most volatile stocks in HK Market | 13.7% |
10% least volatile stocks in HK Market | 3.6% |
Stable Share Price: 2348 has not had significant price volatility in the past 3 months.
Volatility Over Time: 2348's weekly volatility (3%) has been stable over the past year.
About the Company
Founded | Employees | CEO | Website |
---|---|---|---|
1995 | 1,143 | Weixian Wu | www.dawnrays.com |
Dawnrays Pharmaceutical (Holdings) Limited, an investment holding company, develops, manufactures, and sells non-patented pharmaceutical medicines in Mainland China and internationally. It operates in two segments, Intermediates and Bulk Medicines, and Finished Drugs. The company offers antibiotics, including pharmaceutical intermediates, bulk medicines, powder for injections, and oral antibiotics.
Dawnrays Pharmaceutical (Holdings) Limited Fundamentals Summary
2348 fundamental statistics | |
---|---|
Market cap | HK$1.70b |
Earnings (TTM) | HK$354.74m |
Revenue (TTM) | HK$1.25b |
4.8x
P/E Ratio1.4x
P/S RatioIs 2348 overvalued?
See Fair Value and valuation analysisEarnings & Revenue
2348 income statement (TTM) | |
---|---|
Revenue | CN¥1.15b |
Cost of Revenue | CN¥522.67m |
Gross Profit | CN¥628.48m |
Other Expenses | CN¥302.48m |
Earnings | CN¥326.00m |
Last Reported Earnings
Dec 31, 2023
Next Earnings Date
n/a
Earnings per share (EPS) | 0.22 |
Gross Margin | 54.60% |
Net Profit Margin | 28.32% |
Debt/Equity Ratio | 4.2% |
How did 2348 perform over the long term?
See historical performance and comparison